To study the availability of new launched drugs of Zydus Cadila Market Research was carried out in two cities of Gujarat- Ahmedabad and Rajkot- which gave an insight about the availability of newly launched products in medical stores. It also contains area wise availablity and leading brands.

1. MARKET RESEARCH CONDUCTED ON
NEW LAUNCHED PRODUCTS OF
ZYDUS CADILA
Project Manager: Mrs. Babita Goyal
(Strategic Marketing Cell)
Survey conducted, analysed and presented by
Jay Nirmal

2. INTRODUCTION
 Indian pharmaceutical market reached US$ 21.72
billion ( as of June 2011).
 It is growing at the rate of 8-9% annually.
 Thousands of new products are launched each
year.
 Zydus Cadila has come up with many new products
in recent past.

3. RESEARCH OBJECTIVE
To check out the availability of new
launched products of Zydus
Cadila

4. RESEARCH METHODOLOGY
 Type of Research Design:
 Descriptive research
 Sample Design:
 Probability sampling
 Stratified Random sampling
 Sampling Frame:
 Medical store
 Sample Size:
 175
 Data Collection:
 Primary data is collected through Schedules

5. MOLECULES BRANDS
Lacosamide Lacasa
Sodium Valproate Epima Chrono
Telmisartan Inditel, Inditel AM
Metoprolol Sustamet, Sustamet AM
Rosuvastatin Zyrova, Zyrova F

6. Selling
 Total selling of
Lacosamide molecule=
2795 Tablets
 Total selling of Lacasa=
0
 % selling= 0%
Selling
 Total selling of
Lacosamide molecule=
Not found
 Total selling of Lacasa=
Not found
 % selling= --
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

7. Availability
 No. of medical stores
having Lacosamide
molecule = 13
 No. of medical stores
having Lacasa brand= 0
 % availability= 0%
Availability
 No. of medical stores
having Lacosamide
molecule = 4
 No. of medical stores
having Lacasa brand= 1
 % availability= 25%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

8. Known
 No. of medical stores not
having Lacasa= 13
 No. of medical store that
did not knew about this
brand= 12
 % unknown= 92.30%
Known
 No. of medical stores not
having Lacasa= 3
 No. of medical store that
did not knew about this
brand= 3
 % unknown= 100%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

9.  Highest selling brands  Highest selling brands
AHMEDABAD RAJKOT
0
2
4
6
8
10
12
14
Preffered
0
0.5
1
1.5
2
2.5
Preffered
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

10. Selling
 Total selling of Sodium
Valproate molecule=
43240 Tablets
 Total selling of Epima
Chrono= 55
 % selling= 0.13%
Selling
 Total selling of Sodium
Valproate molecule=
15750 Tablets
 Total selling of Epima
Chrono= 1050
 %selling= 6.67%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

11. Availability
 No. of medical stores
having Sodium Valproate
molecule = 94
 No. of medical stores
having EpimaChrono
brand= 8
 % availability= 8.51%
Availability
 No. of medical stores
having Sodium Valproate
molecule = 68
 No. of medical stores
having EpimaChrono
brand= 10
 % availability= 14.71%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

12. Known
 No. of medical stores not
having Epima Chrono=
86
 No. of medical store that
did not knew about this
brand= 68
 % unknown= 79.07%
Known
 No. of medical stores not
having Epima Chrono=
58
 No. of medical store that
did not knew about this
brand= 42
 % unknown= 72.41%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

13. AHMEDABAD RAJKOT
 Highest selling brands  Highest selling brands
0
10
20
30
40
50
60
70
80
90
Valparin
Valprol
Enchorate
Epilex
Torvate
Valprosin
Diva
Diprox
Pref
fere
d
0
10
20
30
40
50
60
Valparin
Epilex
Valprol
Enchorate
Valprosin
Preferred
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

14. Selling
 Total selling of Telmisartan
molecule= 33890 tabs
 Total selling of Inditel= 2900 tabs
 Total selling of Inditel AM= 2340
tabs
 Combined selling= 5240 tabs
 % selling= 15.46%
Selling
 Total selling of Telmisartan
molecule= 18000 tabs
 Total selling of Inditel= 3075 tabs
 Total selling of Inditel AM= 1790
tabs
 Combined selling= 4865 tabs
 % selling= 27.03%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

15. Availability
 No. of medical stores having
Telmisartan molecule = 97
 No. of medical stores having
Inditel brand= 60
 % availability= 70.27%
 No. of medical stores having
Inditel AM brand= 58
 % availability= 61.85%
Availability
 No. of medical stores having
Telmisartan molecule = 67
 No. of medical stores having
Inditel brand= 38
 % availability= 72.41%
 No. of medical stores having
Inditel AM brand= 32
 % availability= 60%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

16. Known
 No. of medical stores not
having Inditel= 37
 No. of medical store that
did not knew about this
brand= 26
 % unknown= 70.27%
Known
 No. of medical stores
not having Inditel= 29
 No. of medical store
that did not knew about
this brand= 21
 % unknown= 72.41%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

17.  Combination
Combina
tion sold
(Out of
97)
-H -AM
No. of
medical
stores
69 57
% of
medical
stores
71.13 58.76
AHMEDABAD RAJKOT
Combination
Combi
nation
sold
(Out
of 67)
-H -AM
Other
s
No. of
medic
al
stores
19 8 3
% of
medic
al
stores
28.36 11.94 4.48
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

18.  Highest selling brands
AHMEDABAD RAJKOT
 Highest selling brands
0
10
20
30
40
50
60
70
80
90
Telma
Telsar
Telsartan
Telpres
Telmikind
Telvas
Tazloc
Telista
Others
P
re
ff
0
5
10
15
20
25
30
35
Telsar
Telma
Telsartan
Telmikind
Tazloc
Telvas
Telista
Telpres
Others
P
re
ff
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

19. Selling
 Total selling of Metoprolol
molecule= 44665 tabs
 Total selling of Sustamet= 1335
tabs
 Total selling of Sustamet AM=
845 tabs
 Combined selling= 2180 tabs
 % selling= 4.88%
Selling
 Total selling of Metoprolol
molecule= 13525 tabs
 Total selling of Sustamet= 810
tabs
 Total selling of Sustamet AM= 30
tabs
 Combined selling= 840 tabs
 % selling= 6.21%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

20. Availability
 No. of medical stores having
Metoprolol molecule = 92
 No. of medical stores having
Sustamet brand= 34
 % availability= 36.96%
 No. of medical stores having
Sustamet AM brand= 29
 % availability= 31.53%
Availability
 No. of medical stores having
Metoprolol molecule = 68
 No. of medical stores having
Sustamet brand= 12
 % availability= %
 No. of medical stores having
Sustamet AM brand= 9
 % availability= 66.67%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

21. Known
 No. of medical stores not
having Sustamet= 58
 No. of medical store that
did not knew about this
brand= 44
 % unknown= 75.86%
Known
 No. of medical stores not
having Sustamet= 56
 No. of medical store that
did not knew about this
brand= 35
 % unknown= 62.5%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

22.  Combination sold  Combination sold
AHMEDABAD RAJKOT
Combination
sold (Out of
92)
-AM
No. of medical
stores
40
% of medical
stores
43.48
Combination
sold (Out of
68)
-AM
No. of medical
stores
3
% of medical
stores
4.11
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

23.  Highest selling brands  Highest selling brands
AHMEDABAD RAJKOT
0
5
10
15
20
25
30
35
40
45
50
Metolar
Betaloc
Metpure
Metocard
MetXL
Seloken
Supermet
Prolomet
Others
Preff
ered
0
5
10
15
20
25
30
35
40
Metolar
Betaloc
Metocard
Metpure
Seoken
Metzor
Prolomet
Metprin
Others
Preff
ered
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL ROSUVASTATIN

24. Selling
 Total selling of Rosuvastatin
molecule= 25325 tabs
 Total selling of Zyrova= 490 tabs
 Total selling of Zyrova F= 25 tabs
 Combined selling= 515 tabs
 % selling= 2.03%
Selling
 Total selling of Rosuvastatin
molecule= 13525 tabs
 Total selling of Zyrova= 810 tabs
 Total selling of Zyrova F= 30 tabs
 Combined selling= 840 tabs
 % selling= 6.21%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL
ROSUVA-
STATIN

25. Availability
 No. of medical stores having
Rosuvastatin molecule = 90
 No. of medical stores having
Zyrova brand= 15
 % availability= 16.67%
 No. of medical stores having
Zyrova F brand= 10
 % availability= 11.11%
Availability
 No. of medical stores having
Rosuvastatin molecule = 90
 No. of medical stores having
Zyrova brand= 15
 % availability= 29.41%
 No. of medical stores having
Zyrova F brand= 7
 % availability= 13.72%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL
ROSUVA-
STATIN

26. Known
 No. of medical stores not
having Zyrova= 75
 No. of medical store that
did not knew about this
brand= 59
 % unknown= 78.66%
Known
 No. of medical stores
not having Zyrova= 36
 No. of medical store
that did not knew about
this brand= 32
 % unknown= 88.89%
AHMEDABAD RAJKOT
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL
ROSUVA-
STATIN

27.  Combination sold  Combination sold
AHMEDABAD RAJKOT
Combination
sold (Out of
90)
-F
No. of medical
stores
30
% of medical
stores
33.33
Combination
sold (Out of
51)
-F
No. of medical
stores
2
% of medical
stores
3.92
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL
ROSUVA-
STATIN

28.  Highest selling brands  Highest selling brands
AHMEDABAD RAJKOT
0
10
20
30
40
50
60
70
80
Rosuvas
Rosucor
Rozavel
Crestor
Rostar
Roset
Others
Preffe
red
0
5
10
15
20
25
30
35
Rosuvas
Roset
Rozavel
Rosucor
Novastat
Rosuv…
Others
Preffe
red
LACOSAMIDE
SODIUM
VALPROATE
TELMISARTAN METOPROLOL
ROSUVA-
STATIN

29. FACTOR AFFECTING AVAILABILITY OF DRUGS
IN MEDICAL STORES
 Preference of Doctor
 Visits of MR
 Affiliated to Physicians/ Hospitals
 Central Location

30. AHMEDABAD
For Zydus Cadila
Preference of Doctor Doctors don’t prescribe much
Stockist availability Available
Pricing
Almost parallel, Not a matter of concern as
long as doctors prescribe
Schemes
Only if purchased in bulk, Not a matter of
concern as long as doctors prescribe
Side effect/ Drug interaction Not aware
Visits of MR
Not regular, in large medical stores and
stores affiliated to hospitals

31. RAJKOT
For Zydus Cadila
Preference of Doctor Doctors don’t prescribe much
Stockist availability Available
Pricing
Almost parallel, Not a matter of concern as
long as doctors prescribe
Schemes Only if purchased in bulk
Side effect/ Drug interaction Unaware, Not a factor
Visits of MR
Not regular, in large stores, no push for
some brands

32. FEEDBACK FROM MEDICAL STORE OWNERS
 Better brands available in market
 Running and set brands already available, no space
for new products
 Infrequent or less visits of MR even though a
particular brand sells or is at least kept in the
medical store
 MRs not much interested in selling
 Push for brands in major medical stores only, in
major locations
 Brands still not popular, most medical owners
haven't even heard the names
 Little trust on Zydus Cadila products

33. SUGGESTIONS FOR AVAILABILITY IN
AHMEDABAD
Lacasa
 Reaching out to particular hospitals and MR visits to
medical stores affiliated with these hospitals can help
enhance availability
Epima Chrono
 Explaining Doctors for its pharmacological superiority
can help
Inditel
 Utility branding for this molecule
 Marketing Hydrothiazide combination may enhance the
sell.

34. Sustamet
 Marketing the molecule to major physicians and
smaller hospitals and then gradually to larger
hospitals.
Zyrova
 More MR interaction with the Medical store owners
and regular visit to Doctors can help.

35. SUGGESTIONS FOR AVAILABILITY IN RAJKOT
Lacasa
 Not much market deveolped for Lacosamide, an early
call for its marketing may help capture the pie.
Epima Chrono
 Explaining Doctors for its pharmacological superiority
can help.
Inditel
 Utility branding for this molecule
 Marketing Hydrothiazide combination may enhance the
sell.

36. Sustamet
 More MR interaction with the Medical store owners
and regular visit to Doctors can help.
Zyrova
 More MR interaction with the Medical store owners
and regular visit to Doctors can help.

37. CONCLUSION
 As seen from the survey conducted, availability of
drugs are heavily dependent on prescription of
doctors, MR follow ups and to what extent the
brands are known by medical store owners.
 Working on these three factors will help in
achieving the objective.

39. Any Questions???